

FORM-PTO-1390
(Rev. 12-29-99)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

000500-285

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.51)

To be assigned 09/763292

INTERNATIONAL APPLICATION NO.

PCT/SE99/01449 ✓

INTERNATIONAL FILING DATE

25 August 1999 ✓

PRIORITY DATE CLAIMED

28 August 1998 ✓

TITLE OF INVENTION

A METHOD FOR MEASURING A PATIENT'S ABILITY TO METABOLISE CERTAIN DRUGS ✓

APPLICANT(S) FOR DO/EO/US

Dan HAUZENBERGER ✓

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and the PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
- ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.

☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:

Published PCT International Application (WO 00/12757) w/ Amended Claims
Sequence Listing (hard copy & computer readable diskette)
IPER
Letter to WIPO regarding change of applicant's name (filed February 2, 2001)

Fet

U.S. APPLICATION NO. (If known, use 37 C.F.R. 1.52) **09/1763292** To be assigned INTERNATIONAL APPLICATION NO. PCT/SE99/01449 ATTORNEY'S DOCKET NUMBER 000500-285

17. ☒ The following fees are submitted:

CALCULATIONS

PTO USE ONLY

Basic National Fee (37 CFR 1.492(a)(1)-(5)):

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1,000.00 (960)

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 (970)

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 (958)

International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 (956)

International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 (962)

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$ 1,000.00

Surcharge of \$130.00 (154) for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).

20 ☐ 30 ☒

\$ 130.00

Claims	Number Filed	Number Extra	Rate		
Total Claims	18 - 20 =	0	0 X \$18.00 (966)	\$	
Independent Claims	8 - 3 =	5	5 X \$80.00 (964)	\$	400.00
Multiple dependent claim(s) (if applicable)			+ \$270.00 (968)	\$	

TOTAL OF ABOVE CALCULATIONS =

\$ 1,530.00

Reduction for 1/2 for filing by small entity, if applicable (see below).

\$ -

SUBTOTAL =

\$ 1,530.00

Processing fee of \$130.00 (156) for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)).

20 ☐ 30 ☐

\$

+

TOTAL NATIONAL FEE =

\$ 1,530.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 (581) per property +

\$

TOTAL FEES ENCLOSED =

\$ 1,530.00

Amount to be:
refunded \$

charged \$

- a. ☐ Small entity status is hereby claimed.
- b. ☒ A check in the amount of \$ 1,530.00 to cover the above fees is enclosed.
- c. ☐ Please charge my Deposit Account No. 02-4800 in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.
- d. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4800. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Ronald L. Grudziecki
BURNS, DOANE, SWECKER & MATHIS, L.L.P.
P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

SIGNATURE

Donna M. Meuth

NAME

36,607

REGISTRATION NUMBER

February 21, 2001

SCANNED 4 20

Patent
Attorney's Docket No. 000500-285

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
)
Dan HAUZENBERGER) Group Art Unit: Unassigned
)
Application No.: Unassigned) Prior Examiner: Unassigned
)
Filed: February 21, 2001)
)
For: A METHOD FOR MEASURING A)
PATIENT'S ABILITY TO)
METABOLIZE CERTAIN DRUGS)
(as amended))

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to the examination of the above-identified patent application, please enter the following amendments.

IN THE TITLE

Please amend the title to read --A METHOD FOR MEASURING A PATIENT'S ABILITY TO METABOLIZE CERTAIN DRUGS--.

IN THE ABSTRACT

A new Abstract is attached.

IN THE CLAIMS

Please amend the claims as follows.

Claim 2, line 1, change "characterized in that" to --wherein--.

Claim 3, line 1, change "anyone of claim 1 or claim 2, characterized in that" to

--claim 1, wherein--.

Claim 16, line 1, change "16 A kit" to --A kit--;

line 3, change "anyone of claims 4-9" to --claim 4--.

Claim 17, line 3, change "anyone of claims 10-12" to --claim 10--.

Claim 18, line 3, change "anyone of claims 13-15" to --claim 13--.

REMARKS

Prior to examination of the above-identified application, entry of the foregoing, and consideration of the above amendments are respectfully requested.

The claims have been amended to delete the multiple dependency.

Favorable action in the form of a Notice of Allowance is respectfully requested.

In the event that there are any questions relating to this amendment, or to the application in general, it would be appreciated if the Examiner would telephone the undersigned attorney at 508-339-3684 concerning such questions so that prosecution of this application may be expedited.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 

Donna M. Meuth

Registration No. 36,607

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: February 21, 2001

--ABSTRACT

It has now turned out that it is possible to carry out a simple test for measuring a patient's ability to metabolize a certain drug by applying a method comprising the steps of a) isolating and/or providing detectable amounts of single-stranded DNA from said sample by using known methods; b) hybridizing the single-stranded DNA obtained in step a) with a
5 detection primer comprising a plurality of nucleotide residues, said primer being complementary to a target nucleotide sequence immediately adjacent and 5' in relation to a defined point mutation of a single-stranded DNA encoding a cytochrome P450 isoform, where said point mutation is known to affect said isoform's ability to metabolize said drug, such that there are no nucleotide residues between the defined point mutation and the 3' end
10 of the detection primer that are identical to the first or second nucleotide residues of the point mutation to be detected, when the detection primer is hybridized to the target nucleic acid; c) extending the primer using a polymerizing agent in a mixture comprising one or more nucleoside triphosphates wherein the mixture includes at least one nucleoside triphosphate complementary to either the first or second nucleic residue comprising means
15 for detecting the incorporation of the nucleoside triphosphate in a nucleic acid polymer, and optionally one or more chain terminating nucleoside triphosphates; d) detecting the incorporation of the nucleoside triphosphate using said means, whereby it is determined whether said sample contains said point mutation of said cytochrome P450 isoform.--

**A METHOD FOR MEASURING A PATIENT'S ABILITY TO METABOLISE
CERTAIN DRUGS**

The present application relates to an assay method for monitoring metabolism of certain drugs in an individual. More particularly, the invention relates to a method for
5 determining the presence of point mutations in isoforms of cytochrome P450, which point mutations are known to affect the isoforms' abilities to metabolise said drugs. The invention also relates to primers and diagnostic kits that are suitable for carrying out the invention.

10 **Technical background**

All reference cited in the following description are incorporated into the disclosure by reference.

15 Single nucleotide variations have been estimated to occur in a frequency of approximately one out of thousand nucleotides in the human genome (Cooper et al., J. Hum. Genet. (1985) 69:201). Many of these mutations may not give rise to a phenotype but a great number of the genetic diseases known to date are caused by single nucleotide polymorphisms. As a consequence, detection of single nucleotide mutations in specific
20 genes will become of increasing interest in order to understand the ethiology of many genetic diseases.

Drug metabolism involves enzymes that either oxidise (phase I) or conjugate (phase II) xenobiotics. The major route of phase I drug metabolism is maintained by a group of
25 enzymes termed cytochrome P450 which are located in the endoplasmatic reticulum primarily in the liver (Linder et al., Clinical Chemistry (1997) 43:254). Cytochromes P450 (CYP) are comprised by a super gene family of mixed function oxidases that metabolises a large number of xenobiotics including drugs. Thirty or more of these enzymes have been characterised in the human so far, each with distinct catalytic
30 specificity and unique regulation. Because of the diversity of these enzymes, they have been subdivided into subpopulations or isoforms based on their sequence homology, The

polymorphism of the catalytic abilities of these enzymes result in the appearance of different phenotypes with differential capacities to metabolise drugs. Extensive metabolism (EM) of a drug is characteristic of the normal population and represents the wild-type allele, poor metabolism (PM) is due to poor or no catalytic capacity by a specific enzyme, in most cases due to mutations or deletions of the gene, whereas ultra-extensive metabolism (UEM) in general is caused by gene duplications.

The most important isoforms involved in drug metabolism are CYP2D6, CYP2C9, CYP2C19 and CYP3A4. Several of these CYP isoforms are known to be polymorphic which results in differential capacities in metabolising drugs such as omeprazole (proton pump inhibitors), phenytoin (anti-convulsant), verapamil (calcium-antagonists), propranolol (beta-blockers) and many others. The CYP2C9 isoform is involved in hydroxylation of tolbutamide, phenytoin and S-warfarin among others. Specifically, CYP2C9 converts S-warfarin into the inactive phenolic metabolite S-7-hydroxywarfarin and thereby controls the pharmacological activity of this drug. Here too, polymorphisms among these enzymes exist resulting in differential capacities to metabolise drugs. The genetic basis of this polymorphism is single nucleotide mutations resulting in the expression of two allelic variants, CYP2C9*2 and CYP2C9*3. The CYP2C9*2 allele has cysteine substituted for arginine at amino acid 144 in the protein and CYP2C9*3 has leucine substituted for isoleucine at position 359. The frequencies of these alleles have been reported to be between 7 and 19 % in Caucasian populations. Although homozygous individuals for these alleles are relatively uncommon, *in vitro* studies of the metabolism of warfarin have shown impaired catalytic ability by these variant proteins (Steward et al., Pharmacogenetics (1997) 7:361). For instance, CYP2C9*3 possesses only 5% of the catalytic capacity for S-warfarin as compared to the CYP2C9 wild type enzyme.

Warfarin is a widely used anticoagulant of coumarin type which acts by blocking synthesis of the vitamin K-dependant coagulation factors II, VII, IX and X in the liver. The indications for taking S-warfarin are all diseases where prevention of extensive blood clotting is a crucial factor in the efficient treatment of patients. Examples of such

diseases are acute embolic diseases of heart, lung or brain. In these cases the treatment is often combined with heparine. More specific indications are diseases where a lifelong treatment with anti-coagulants is required. Such diseases include recurrent venous thrombosis, pulmonary embolism and chronic atrial fibrillations. The major difficulties with the use of this drug are a broad range of interactions with other drugs as well as nutritional factors. The complicated treatment of patients with this drug carries the risk of serious hemorrhage in as much as 9 % per patient year (Fihn et al., Ann. Intern. Med. (1996) 124:970; Steward et al., Pharmacogenetics (1997) 7:361). Therefore, pretreatment evaluation of the CYP2C9 status of potential patients to be treated with warfarin would significantly reduce the risk of adverse drug reactions. Moreover, CYP2C9 metabolises the transformation of the anti-convulsant Valproic acid (VDA) into the unsaturated metabolite 4-ENE-VPA. 4-ENE-VPA acts hepatotoxic and causes several deaths yearly in the US (Sadeque et al., J. Pharmacol. Exp. Ther. (1997) 283:698).

The CYP2C19 isoform is involved in 4-hydroxylation (or 5-hydroxylation) of tricyclic antidepressants such as imipramin, anti-malarial prodrugs as for instance proguanil and proton pump inhibitors such as omeprazole or pantoprazole (Linder et al., Clinical Chemistry (1997) 43:254). This subfamily is polymorphogenic due to single nucleotide mutations (SNP) of the wild type allele. The M1 allele contains a G₆₈₆-A₆₈₆ substitution which creates a novel aberrantly spliced CYP2C19 mRNA. This results in the production of an inactivated truncated protein. The M2 allele contains a G₆₄₁-A₆₄₁ substitution resulting in a premature stop codon. Therefore, these two alleles represent poor metabolise phenotypes.

Detection of single-point mutations (SNP), such as the above mentioned mutations, can be performed using different techniques. In general, such assays can be subdivided into techniques where detection of SNP:s involves electrophoretic separation of DNA sequences and techniques using solid supports. Techniques using solid supports have several advantages as compared to electrophoretic separation techniques. Firstly, the solid-phase assays involve relatively few and simple manipulations that are amenable to full automation. Secondly, non-radioactive methods can conveniently be used in the solid

phase assays and thirdly, these assays give numerical results allowing e.g. statistical treatment.

As in the case of solid phase assays, different assay types may be distinguished. These techniques include hybridisation with sequence-specific oligonucleotide probes such as "reverse dot blot" or sandwich hybridisation. These techniques require very careful design of the sequence-specific probes and close monitoring of reaction conditions and may thus only be performed in highly specialised laboratories. Similar problems are encountered with sequence-specific amplification which require careful optimisation of the PCR conditions. Here too, only highly specialised laboratories are capable of performing this technique. Finally, sequencing of defined DNA sequences requires a costly infrastructure and trained personnel which currently only can be provided at highly specialised laboratories.

Since the CYP2C19 and CYP2C9 enzymes metabolise a variety of drugs where relative overdosing poses a potential threat to the patient's health, there is need for a simple analytical test clarifying the genetic status of the individual prior to drug intake, as knowledge of a person's genetic status prior to drug intake could substantially reduce the risk for adverse drug reactions.

Summary of the invention

It has now turned out that it is possible carry out a simple test for measuring a patient's ability to metabolise a certain drug by applying a method comprising the steps of

- a) isolating and/or providing detectable amounts of single-stranded DNA from said sample by using known methods;
- b) hybridising the single-stranded DNA obtained in step a) with a detection primer comprising a plurality of nucleotide residues, said primer being complementary to a target nucleotide sequence immediately adjacent and 5' in relation to a defined point mutation of a single-stranded DNA encoding a cytochrome P450 isoform, where said point mutation is known to affect said isoform's ability to metabolise said drug, such

that there are no nucleotide residues between the defined point mutation and the 3' end of the detection primer that are identical to the first or second nucleotide residues of the point mutation to be detected, when the detection primer is hybridised to the target nucleic acid;

- 5 c) extending the primer using a polymerising agent in a mixture comprising one or more nucleoside triphosphates wherein the mixture includes at least one nucleoside triphosphate complementary to either the first or second nucleic residue comprising means for detecting the incorporation of the nucleoside triphosphate in a nucleic acid polymer, and optionally one or more chain terminating nucleoside triphosphates;
- 10 d) detecting the incorporation of the nucleoside triphosphate using said means, whereby it is determined whether said sample contains said point mutation of said cytochrome P450 isoform.

Detailed description of the invention

15 The solid phase mini-sequencing technique disclosed in WO91/13075 provides a cheap and robust assay which can be performed by any laboratory equipped with a thermal cycler. Moreover, this technique does not require any specially trained personnel. Furthermore, the solid phase mini-sequencing technique does not require radioactively
20 labeled nucleotides. Therefor it exhibits higher safety standards than such techniques. Finally, this technique provides an excellent possibility of detecting either homozygote or heterozygote alleles within a defined sample.

25 Accordingly, the present invention relates to a method for determining the ability of cells in a sample to metabolise a certain drug comprising detecting a defined point mutation of a single-stranded DNA encoding a cytochrome P450 isoform, where said point mutation is known to affect said isoform's ability to metabolise said drug.

30 In another embodiment the present invention relates to detection primers useful in the above mentioned method, which primers hybridise to target nucleotide sequences

immediately adjacent and 5' in relation to a point mutation of a DNA, said DNA encoding an isoform of cytochrome P450.

In yet another embodiment, the present invention relates to a diagnostic kit for carrying out said method, said kit comprising at least one detection primer as defined above, at least two amplification primers derived from a sequence encoding a cytochrome P450 isoform, said amplification primers being chosen in such a way that a subsequence of said cytochrome P450-encoding sequence to which said detection primer hybridises is amplified, and a DNA-polymerising agent.

As disclosed herein, the term "drug" relates to drugs that are metabolised by cytochrome P450 isoforms. Examples of such drugs are omeprazole, pentaprazole, phenytoin, verapamil, propranolol, tolbutamide, S-warfarin, tricyclic antidepressants such as imipramin and anti-malarial prodrugs such as proguanil.

As disclosed herein, the term "detection primer" relates to an oligonucleotide which hybridises to a site immediately adjacent 5' in relation to a defined point mutation. The term "amplification primer" relates to one of two primers forming a primer pair that is used according to well-known amplification procedures such as PCR. Both detection primers and amplification primers according to the invention comprises 8 - 70 nucleotides, preferably 10-30 nucleotides, and most preferably 15 - 25 nucleotides.

As disclosed herein, the term "affinity pair" relates to a pair of chemical, preferably biochemical, compounds that binds specifically and strongly to each other. Examples of such pairs include, but are not limited to antibody-antigen, biotin-avidin/streptavidin, enzyme-substrate, a pair of complementary oligonucleotides, protein A-IgG, etc.

As disclosed here, the term "polymerising agent" relates to a DNA polymerising agent. An example of such an agent is the Klenow fragment of Escherichia coli DNA polymerase I, but any DNA polymerase can be used in the method of this invention.

According to the present invention, the presence of point mutations can be detected by adding labelled nucleotides to the detection primer. Any kind of detectable labels, such as one member of an affinity pair, radioactive nuclides, fluorescent compounds, enzymes inducing light emissions or colour changes etc. can be bound to an ordinary nucleotide in order to obtain a labelled nucleotide. Alternatively, it is possible to use modified nucleotides such as chain-terminating dideoxynucleotides. The skilled person is well aware of how to choose suitable labelled nucleotides as well as how to choose suitable detection procedures when carrying out the method according to the present invention.

The present invention will now be further described with reference to the enclosed figure and tables, in which:

fig. 1 discloses a photo of an electrophoresis gel where lanes A-E represent the following PCR products: A: CYP2C9*2 (simplex PCR), B: CYP2C9*3 (simplex PCR), C:

CYP2C9*2*3 (20 μ l*3, multiplex PCR), D: CYP2C9*2*3 (15 μ l * 3, multiplex PCR), E: CYP2C9*2*3 (10 μ * 3, multiplex PCR). In the multiplex PCR

constant primer concentrations for the CYP2C9*2 allele and decreasing concentrations of primers for the CYP2C9*3 allele were used in order to optimise the multiplex PCR conditions;

table 1 discloses results obtained when the PCR products shown in fig. 1 have been subjected to minisequencing reactions. Both specific and non-specific sequence primers as well as complimentary or non-complimentary nucleotides have been used. The figures shown in table 1 represent optical density (OD) values from an ELISA determined at 405 nm. The table shows which PCR products were coated onto the streptavidin-coated ELISA plate (columns), which sequence primers were used (rows) and which nucleotides were used in the sequencing reaction (columns);

table 2 shows the calculated ratio of the OD at 405 nm from nucleotides incorporated by the mini-sequencing reaction. The ratio values presented in this table have been

calculated from the OD values in table 1. The ratio was calculated as follows:
complementary nucleotide (OD at 405 nm/ complementary nucleotide + non-
complementary nucleotide (OD at 405 nm). A ratio of > 0.85 is significant for an
incorporation of complementary nucleotides when using homozygous alleles.

5

Experimental procedures

The mini-sequencing technique is based on amplification of defined genes with PCR
(Polymerase Chain Reaction) using biotinylated or otherwise conjugated oligonucleotides
(primers). In general, where possible a multiplex amplification procedure is utilised.
Following amplification, the biotinylated PCR products are immobilised on streptavidin-
coated microwell plates and the PCR products are sequenced using an allele-specific
oligonucleotide. Possible mutations within the immobilised PCR product representing a
defined allele are detected by incorporation of a mutation-specific labelled nucleotide.
Incorporation of a complementary nucleotide can be detected either directly or indirectly
utilising various established detection methods. Using this technique, it is possible to
detect homozygote or heterozygote alleles based on single nucleotide mutations within an
individual.

- 20 Genomic DNA can be prepared using any established method described in the literature
(PCR Protocols, Innis MA et al., Academic Press 1990; PCR, a practical approach,
McPherson, MJ et al., Oxford University Press, 1991) or using any DNA purification kit
present. The DNA prepared in these experiments has been prepared using the QIAamp
Blood Kit (Qiagen Inc, USA) according to the description provided by the manufacturer.
- 25 Genomic DNA can be prepared using any sample-containing nucleated cells. The typical
yield using the above mentioned DNA purification kit is 10 ng/ μ l. 250 ng of purified
genomic DNA was used as a template in the subsequent PCR. The primers used for the
PCR reactions are described in the sequence listing as SEQ.ID.Nos 4, 5, 7, 8, 10, 11, 13
and 14. In the following description of the experimental procedures for the PCR and
- 30 mini-sequencing method of CYP genes, primers specific for the CYP2C9 alleles were

used. The same experimental procedures as described below were used when CYP2C19 alleles were studied with the exception for using CYP2C19-specific oligonucleotides.

A 2x mastemix for the multiplex PCR of CYP2C9 alleles was prepared as follows:

- Tris-HCl (100 mM, pH8.8)
- $(\text{NH}_4)_2\text{SO}_4$ (30 mM)
- Triton X-100 (0.2 % vol./vol.)
- Gelatin (0.02% wt/vol.)
- dNTPs (0.4 μM)
- SEQ.ID.NO. 4, 5, 7, 8 (0.4 mM of each)
- MgCl_2 (3.0 mM)
- ddH₂O up to 500 μl

For the PCR reaction 50 μl of the above described 2x mastermix was subject to a PCR tube (thin wall PCR tubes, Perkin-Elmer Inc. USA). 24,5 μl of ddH₂O, 0,5 μl Taq-polymerase (2,5 Units, Perkin-Elmer, Inc, USA) and 25 μl geonomic DNA (250 ng) was added to the tube and the reaction mix was overlaid with 50 μl mineral oil.

The thermal conditions for amplification of the CYP2C9 alleles were as follows:

An initial denaturation step at 96°C for 2 minutes thereafter 96°C (30 sec), 60°C (30 sec) (58°C for the CYP2C19 alleles) and 72°C (30 sec), 35 cycles. Following the PCR amplification, 100 μl of the amplified sample was mixed with 400 μl of Binding buffer (buffer 1) containing 20 mM sodium phosphate, pH 7.5, 100 mM NaCl and 0.1 % (v/v) Tween-20.

50 μl aliquots were subsequently transferred to streptavidin coated said phase, such as microwell plates (MWP) which are commercially available (Labsystems, Helsinki, Finland). The MWP were then incubated at 22°C for 15 minutes. Following incubation, the immobilized PCR samples were denatured using a denaturing solution containing NaOH (50 mM) for 1 minute at 22°C. The MWP were washed using a buffer (buffer 2)

containing Tris-HCl (40 mM, pH 8.8), EDTA (1mM), NaCl (50 mM) and Tween-20 (0.1%).

For the minisequencing reaction, every well of the MWP was incubated with an appropriate minisequencing primer (final concentration 0.1 μ M) diluted in 5 μ l of 10 x DNA polymerase buffer (buffer 3) containing Tris-HCl (500 mM, pH 8.8), $(\text{NH}_4)_2\text{SO}_4$ (150 mM), MgCl_2 (15mM), Triton X-100 (1% V/V), Gelatin (0.1%W/V), DNA polymerase (0.1 units), fluorescein-12-dNTP complementary to the nucleotide to be detected (final concentration of 0.1 μ M) and ddH₂O to a final volume of 50 μ l.

The MWP were incubated at 55° C for 30 minutes. Following the minisequencing reaction the MWP were washed using buffer 2. Incorporated nucleotides were detected using alkaline phosphatase (AP) conjugated anti-FITC monoclonal antibodies (0.75 U/ml) diluted in a buffer (buffer 4) containing : Hepes (25 mM), NaCl (125 mM), MgCl_2 (2 mM), BSA (1%) and Tween-20 (0.3 % V/V). Incubation was done at 22° C for 15 minutes and the plates were subsequently washed using buffer 2. Detection of bound monoclonal antibodies was performed by incubation the MWP using a detection buffer (buffer 5) containing diethanolamine (10.6 % W/V), MgCl_2 (0.05 % W/V) and para-nitro-phenyl phosphate (4 mg/ml) for 20 minutes at 22° C. Detection of incorporated dNTP's was done at 405 nm using a commercially available spectrophotometer.

RESULTS

PCR amplification and minisequencing has been performed using CYP2C9 and CYP2C19 specific primers. The results shown below demonstrate amplification and minisequencing of the CYP2C9 alleles. Human genomic DNA was purified as described in the method section. 250 ng of genomic DNA was subjected to PCR as described above. The results of a representative experiment are demonstrated in figure 1.

Next a minsequencing reaction of the amplified DNA was done as described above. By using alleles specific sequencing primers incorporated dNTP's could be detected in subsequent detection steps as described above. These results are shown in table 1.

- 5 In order to obtain numerical values a ratio of the OD was calculated based on the formula shown below. These results are demonstrated in table 2.

These results clearly show that by using gene-specific primers it was possible to amplify and sequence cytochrome P450 specific alleles using PCR and the minsequencing
10 technique as described above.

TABLE I

[illegible]

TABLE 2

PCR Primers	Nucleotide	Ratio
CYP2C9*2	C	0.99
CYP2C9*3	T	0.97
CYP2C9*2*3 (20 μl)	C	0.95
CYP2C9*2*3 (20 μl)	T	0.95
CYP2C9*2*3 (15 μl)	C	0.92
CYP2C9*2*3 (15 μl)	T	0.93
CYP2C9*2*3 (10 μl)	C	0.75
CYP2C9*2*3 (10 μl)	T	0.77

ART 34 AMDT

SEQUENCE LISTING

<110> AB Sangtec Medical

<120> New method

<130> primers

<140> SE9802897-0

<141> 1998-08-28

<160> 19

<170> PatentIn Ver. 2.1

<210> 1

<211> 1746

<212> DNA

<213> Homo sapiens

<400> 1

cttcaatgga tccctttgtg gtccttgtgc tctgtctctc atgtttgctt ctcctttcaa 60
tctggaagaca gagctctggg agaggaaaaac tccctcctgg cccactcct ctcocagtga 120
ttggaatat cctacagata gatattaagg atgtcagcaa atcctcaacc aatctctcaa 180
aaatctatgg cctctgtgtc actctgtatt ttggcctgga acgcattggt gtgctgcatg 240
gatattgaagt ggtgaaggaa gccctgattg atccttgaga ggagttttct ggaagaggcc 300
atttccact ggctgaaaga gctaacagag gatttggaaat cgttttcagc aatggaaaga 360
gatggaagga gattcggcgt ttctccctca tgacgctgcg gaattttggg atggggaaga 420
ggagcattga ggaccgtgtt caagagggaag ccgcctgcct tgtggaggag ttgagaaaaa 480
ccaaggcttc accctgtgat cccactttca tccctggcgt tgctccctgc aatgtgatct 540
gctccattat ttccagaaa cgtttcgatt ataaagatca cgaattttct aacttgatgg 600
aaaaattgaa tgaaaacatc aggattgtaa gcaccocctg gatccagata tgcaataatt 660
ttccactat cattgattat ttcccgga cccataacaa attacttaa aaccttgctt 720
ttatggaaag tgatattttg gagaaagttaa aagaacacca agaactgatg gacatcaaca 780
accctcggga ctttattgat tgcttcttga tcaaaatgga gaaggaaaag caaaaccaac 840
agtctgaatt cactattgaa aacttggtta tcaactgcag tgacttactt ggagctggga 900
cagagacaac agtcacaacc ctgagatatt ctctccttct cctgctgaag caoccagagg 960
tcacagctaa agtccaggaa gagattgaac gtgtcattgg cagaaacogg agcccttgca 1020
tgacagacag gggccacatg cctacacacg atgtctgtgt gcacgaggtc cagagataca 1080
tcgacctcat cccaccacgc ctgccccatg cagtgcactg tgacgttaaa ttcagaaact 1140
acctcattcc caagggcaca accatatata ctccctcac ttctgtgcta catgacaaca 1200
aagaatttcc caaccagag atgtttgacc ctgctcactt tctggatgaa ggtggaaatt 1260
ttaagaaaag taactacttc atgcttttcc cagcaggaaa acggatttgt gtgggagagg 1320
gcttgcccg catggagctg tttttattcc tgaacttcat ttacagaaac ttttaacctg 1380
aatctctgat tgaccocaaag gaccttgaca caactcctgt tgtcaatgga tttgcttctg 1440
tcccgccctt ctatcagctg tcttccatcc ctgtctgaag aagcacagat ggtctggctg 1500
ctctgtgtct gtccttgacg ctctcttctc tctggtccaa atctcactat ctgtgatgct 1560
tcttctgacc cgtcatctca cattttccct tcccccaga tctagtgaac attcagcttc 1620
cattaaaaaa gtttcaactg gcaaatatat ctgtatttcc ccatactcta taatagttac 1680
attgagtgc acataatgct gatacttgct taatgttgag ttattaacat attattatta 1740
aataga 1746

<210> 2

<211> 743

<212> DNA

<213> Homo sapiens

<400> 2

tcagaaatat ttgaagcctg tgtggtgaa taaaagcata caaatacaat gaaaatatca 60
tgctaaatca ggttagcaa atggacaaaa tagtaacttc gtttgcgtgt atctctgct 120
actttcctag ctctcaagg tctatggccc tgtgttcaat ctgtattttg gctgaaacc 180

22-11-2000

PCT/SE99/01449

ART 34 AMDT

SEQ

```

catagtgggtg ctgcatggat atgaagcagt gaaggaagcc ctgattgato ttggaggaga 240
gtttttctgga agaggcattt tcccaactggc tgaagagagct aacagaggat ttggtaggtg 300
tgcattgtgac tgtttcagca tctgtcttgg ggatggggag gatggaaaac agagacttac 360
agagctcctc gggcagagct tggcccatoc acatggctgc ccagtgtcag ctctctcttt 420
cttgccctggg atctccctcc tagtttctgt totcttctg ttaggaattg ttttcagcaa 480
tggaaagaaa tgggaaggaga tccggcggtt ctccctcatg acgctgcgga attttgggat 540
ggggaagagg agcattgagg accgtgttca agaggaagcc cgtgccttg tggaggagt 600
gagaaaaacc aagggtgggt gaacctactc catatocactg accttactgg actactatct 660
totctactga cattcttggg aacatttcag ggggtggccat atcttctatt atgagtcctg 720
ttgttagctc atgtgaagcg ggg

```

<210> 3

<211> 323

<212> DNA

<213> Homo sapiens

<400> 3

```

cccctgaatt gctacaacaa atgtgcaatt tttctcctt tccatcagtt tttacttgtg 60
tcttatcagc taaagtccag gaagagattg aacgtgtgat tggcagaaac cggagccct 120
gcattgcaaga caggagccac atgccttaca cagatgctgt ggtgcacgag gtccagagat 180
acottgacct tctcccccac agcctgcccc atgcagtgc ctgtgacatt aaattcagaa 240
actatctcat tcccaaggta agtttgttct tctacactg caactccatg ttttcgaagt 300
cccaattcca tagtatcatt ttt

```

323

<210> 4

<211> 20

<212> DNA

<213> Homo sapiens

<400> 4

ttacaaccag agcttggcat

20

<210> 5

<211> 20

<212> DNA

<213> Homo sapiens

<400> 5

atcaataaag tcccgagggt

20

<210> 6

<211> 21

<212> DNA

<213> Homo sapiens

<400> 6

aagtaatttg ttatgggttc c

21

<210> 7

<211> 20

<212> DNA

<213> Homo sapiens

<400> 7

tgcaatgtga tctgctccat

20

<210> 8

<211> 20

<212> DNA

<213> Homo sapiens

22-11-2000

82-11-2000

PCT/SE99/01449

ART 34 AMDT

SEQ

<400> 8
gttcagggct tggtaatat 20

<210> 9
<211> 18
<212> DNA
<213> Homo sapiens

<400> 9
gattgtaagc accccctg 18

<210> 10
<211> 21
<212> DNA
<213> Homo sapiens

<400> 10
octagtttgg tttctcttc t 21

<210> 11
<211> 21
<212> DNA
<213> Homo sapiens

<400> 11
cagtgatatg gagtagggc a 21

<210> 12
<211> 18
<212> DNA
<213> Homo sapiens

<400> 12
aagaggagca ttgaggac 18

<210> 13
<211> 20
<212> DNA
<213> Homo sapiens

<400> 13
gtccaggaag agattgaacg 20

<210> 14
<211> 20
<212> DNA
<213> Homo sapiens

<400> 14
catggagttg cagtgttaga 20

<210> 15
<211> 18
<212> DNA
<213> Homo sapiens

<400> 15
tggtggggag aaggtcaa 18

<210> 16
<211> 18

Printed on 12-2000



22-11-2000

PCT/SE99/01449

ART 34 AMDT SEQL

<212> DNA
<213> Homo sapiens

<400> 16
gggcttcctc ttgaacac

18

<210> 17
<211> 18
<212> DNA
<213> Homo sapiens

<400> 17
cacgaggtcc agagatac

18

<210> 18
<211> 19
<212> DNA
<213> Homo sapiens

<400> 18
ctatcattga ttatttccc

19

<210> 19
<211> 22
<212> DNA
<213> Homo sapiens

<400> 19
gaaaattatt gcatatctgg at

22

TUE 10 FEB 2001 14:50

PCT/SE99/01449

18

Amended claims

1. A method for determining the ability of cells in a sample, to metabolise a certain drug, comprising the steps of
- 5 a) isolating and/or providing detectable amounts of single-stranded DNA from said sample by using known methods;
- b) hybridising the single-stranded DNA obtained in step a) with a detection primer comprising a plurality of nucleotide residues, said primer being complementary to a target nucleotide sequence immediately adjacent and 5' in relation to a defined point mutation of a single-stranded DNA encoding a cytochrome P450 iso-
- 10 form, such as i) mutations resulting in an amino acid substitution at amino acid residue 144 of CYP2C9*2; ii) mutations resulting in an amino acid substitution at amino acid number 359; iii) a point mutation at base 686 of a nucleic acid sequence encoding the M1 allele of CYP2C19; and iv) a point mutation at base 641 of a nucleic acid sequence encoding the M2 allele of CYP2C19, where said point mutation is known to affect said isoform's ability to metabolise said drug, when the detection primer is hybridised to the target nucleic acid;
- 15 c) extending the primer using a polymerising agent in a mixture comprising one or more nucleoside triphosphates wherein the mixture includes at least one labelled nucleoside triphosphate complementary to either the first or second nucleic residue, and optionally one or more chain terminating nucleoside triphosphates;
- 20 d) detecting the incorporation of the nucleoside triphosphate using said means, whereby it is determined whether said sample contains said point mutation of said cytochrome P450 isoform.
- 25
2. A method according to claim 1, characterised in that the single-stranded DNA isolated and/or provided in step a) is obtained by performing a modified amplification reaction in which one of the two amplification primers comprises a first attachment moiety bound to the primer, thereby obtaining a double-stranded
- 30 amplification product in which only one of the strands comprises a first attachment moiety, where said first attachment moiety is one half of an affinity pair,

and then simultaneously or sequentially in any order rendering the amplification product single-stranded and immobilising the strand comprising the first attachment moiety to a solid support with the aid of the other component of the affinity pair, whereafter all unbound material is removed.

5

3. A method according to anyone of claim 1 or claim 2, characterised in that said point mutation to be detected only comprises one altered nucleotide.

10

4. A detection primer hybridising to a target nucleotide sequence immediately adjacent and 5' in relation to a point mutation of a single stranded DNA encoding cytochrome P450 isoform CYP2C19, said primer consisting of a subsequence of 10 - 70 nucleotides of the sequence:

5' GTTCTTTTAC TTTCTCCAAA ATATCACTTT CCATAAAAGC
AAGGTTTTTA

15

AGTAATTTGT TATGGCTTCC 3'

which subsequence always comprises the nucleotide located in the 3' end of the sequence above.

20

5. A detection primer according to claim 4 consisting of a subsequence of 10-30 nucleotides.

6. A detection primer according to claim 5 which is 5'-
AAGTAATTTGTTATGGGTTCC-3'.

25

7. A detection primer hybridising to a target nucleotide sequence immediately adjacent and 5' in relation to a point mutation of a single stranded DNA encoding cytochrome P450 isoform CYP2C19, said primer consisting of a subsequence of 10 - 70 nucleotides of the sequence:

30

5'-TTGAATGAAA ACATCAGGAT TGTAAGCACC CCCTGA-
ATCC AGATATGCAA
TAATTTTCCC ACTATCATTG ATTATTTCCC-3'

which subsequence always comprises the nucleotide located in the 3' end of the sequence above.

8. A detection primer hybridising to a target nucleotide sequence immediately adjacent and 5' in relation to a point mutation of a single-stranded DNA encoding cytochrome P450 isoform CYP2C19, said primer consisting of a subsequence of 8 - 50 nucleotides of the sequence:

5'-AACTTGATGG AAAAATTGAA TGAAAACATC AGGATTG-TAA GCACCCCCTG-3'

which subsequence always comprises the nucleotide located in the 3' end of the sequence above.

9. A detection primer according to claim 8 which is: 5'-GATTGTAAGCACCCCCTG-3'.

10. A detection primer hybridising to a target nucleotide sequence immediately adjacent and 5' in relation to a point mutation of a single-stranded DNA encoding cytochrome P450 isoform CYP2C9, said primer consisting of a subsequence of 8 - 50 nucleotides of the sequence:

5'-CCCTCATGAC GCTGCGGAAT TTTGGGATGG GGAAGAG-GAG CATTGAGGAC-3'

which subsequence always comprises the nucleotide located in the 3' end of the sequence above.

11. A detection primer according to claim 10 which is: 5'-AAGAGGAGCATTGAGGAC-3'.

12. A detection primer hybridising to a target nucleotide sequence immediately adjacent and 5' in relation to a point mutation of a single-stranded DNA encoding cytochrome P450 isoform CYP2C9, said primer consisting of a subsequence of 8 - 50 nucleotides of the sequence:

5'-CTTGGTTTTT CTCAACTCCT CCACAAGGCA GCGGGCTTCC
TCTTGAACAC-3'

which subsequence always comprises the nucleotide located in the 3' end of the sequence above.

5

13. A detection primer hybridising to a target nucleotide sequence immediately adjacent and 5' in relation to a point mutation of a single-stranded DNA encoding cytochrome P450 isoform CYP2C9, said primer consisting of a subsequence of 8-50 nucleotides of the sequence:

5'-TTTAATGTCA CAGGTCCTG CATGGGGCAG
GCTGGTGGGG AGAAGGTCAA-3'

which subsequence always comprises the nucleotide located in the 3' end of the sequence above.

15

14. A detection primer according to claim 13, which is: 5'-
TGGTGGGGAGAAGGTCAA-3'.

15. A detection primer hybridising to a target nucleotide sequence immediately adjacent and 5' in relation to a point mutation of a single-stranded DNA encoding cytochrome P450 isoform CYP2C9, said primer consisting of a subsequence of 8-50 nucleotides of the sequence:

5'-GGAGCCACAT GCCCTACACA GATGCTGTGG TGCAC-
GAGGT CCAGAGATAC-3'

which subsequence always comprises the nucleotide located in the 3' end of the sequence above.

25

16. 16 A kit for detecting a possible point mutation in cytochrome P450 isoform CYP2C19 comprising:

- a) a detection primer according to anyone of claims 4-9;
b) two amplification primers derived from the sequence according to SEQ.ID.NO. 1 and a sequence complementary to SEQ.ID.NO. 1, said primers being chosen in

30

ART 34 AMDT

such a way that a subsequence of the sequence according SEQ.ID.NO.1 containing said possible point mutation and a sequence complimentary to said detection primer can be amplified;

- c) at least one labelled nucleoside triphosphate; and
- d) a DNA polymerasing agent.

17. . A kit for detecting a possible point mutation in cytochrome P450 isoform CYP2C9 comprising:

- a) a detection primer according to anyone of claims 10-12;
- b) two amplification primers derived from the sequence according to SEQ.ID.NO. 2 and a sequence complementary to SEQ.ID.NO. 2, said primers being chosen in such a way that a subsequence of the sequence according SEQ.ID.NO.2 containing said possible point mutation and a sequence complimentary to said detection primer can be amplified;
- c) at least one labelled nucleoside triphosphate; and
- d) a DNA polymerasing agent.

18. A kit for detecting a possible point mutation in cytochrome P450 isoform CYP2C9 comprising:

- a) a detection primer according to anyone of claims 13-15;
- b) two amplification primers derived from the sequence according to SEQ.ID.NO. 3 and a sequence complementary to SEQ.ID.NO. 3, said primers being chosen in such a way that a subsequence of the sequence according SEQ.ID.NO.3 containing said possible point mutation and a sequence complimentary to said detection primer can be amplified;
- c) at least one labelled nucleoside triphosphate; and
- d) a DNA polymerasing agent.

1/1

FIG. 1



A: CYP2C9*2, B: CYP2C9*3, C: CYP2C9*2*3 (20 μ l)*3,
D: CYP2C9*2*3 (15 μ l*3), E: CYP2C9*2*3 (10 μ l*3)

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (Includes Reference to Provisional and PCT International Applications)	ATTORNEY'S DOCKET NUMBER
--	---------------------------------

As a below named inventor, I hereby declare that:
 My residence, post office address and citizenship are as stated below next to my name;
 I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

A METHOD FOR MEASURING A PATENT'S ABILITY TO METABOLISE
CERTAIN DRUGS

the specification of which (check only one item below):

☐ is attached hereto.

☒ was filed as United States application
 Number _____
 on _____
 and was amended
 on _____ (if applicable).

☒ was filed as PCT international application
 Number PCT/SE99/01449 ✓
 on 25 August 1999 ✓
 and was amended under PCT Article 19
 on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(e) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

COUNTRY (if PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. §119
Sweden ✓	9802897-0 ✓	28 August 1998 ✓	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

 (Application Number)

 (Filing Date)

 (Application Number)

 (Filing Date)

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (CONTINUED) (Includes Reference to Provisional and PCT International Applications)			ATTORNEY'S DOCKET NO.		
I hereby claim the benefit under Title 35, United States Code, §120 of any United States applications(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the Office all information known to me to be material to the patentability as defined in Title 37, Code of Federal Regulations §1.56, which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:					
PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:					
U.S. APPLICATIONS			STATUS (check one)		
U.S. APPLICATION NUMBER	U.S. FILING DATE	PATENTED	PENDING	ABANDONED	
PCT APPLICATIONS DESIGNATING THE U.S.					
PCT APPLICATION NO.	PCT FILING DATE	U.S. APPLICATION NUMBERS ASSIGNED (if any)			
I hereby appoint the following attorneys and agent(s) to prosecute said application and to transact all business in the Patent and Trademark Office connected therewith and to file, prosecute and to transact all business in connection with international applications directed to said invention:					
William L. Mathis Peter H. Smolka Robert S. Swecker Platon N. Mandros Benton S. Duffett, Jr. Joseph R. Magnone Norman H. Szepko Ronald L. Grudziecki Frederick G. Michaud, Jr. Alan E. Kopecki Regis E. Slotter Samuel C. Miller, III Ralph L. Freeland, Jr.	<u>17,337</u> <u>15,913</u> <u>19,885</u> <u>22,124</u> <u>22,030</u> <u>24,239</u> <u>22,716</u> <u>24,970</u> <u>26,003</u> <u>25,813</u> <u>26,999</u> <u>27,360</u> <u>16,110</u>	Robert G. Mukai George A. Hovanec, Jr. James A. LaBarre E. Joseph Gess R. Danny Huntington Eric H. Weisblatt James W. Peterson Teresa Stanek Rea Robert E. Krebs William C. Rowland T. Gene Dillahunty Patrick C. Keane Bruce J. Boggs, Jr.	<u>28,531</u> <u>28,221</u> <u>28,632</u> <u>28,510</u> <u>27,903</u> <u>30,505</u> <u>26,057</u> <u>30,427</u> <u>25,885</u> <u>30,888</u> <u>25,423</u> <u>32,858</u> <u>32,344</u>	William H. Benz Peter K. Skiff Richard J. McGrath Matthew L. Schneider Michael G. Savage Gerald F. Swiss Michael J. Ure Charles F. Wieland III Bruce T. Wieder Todd R. Walters	<u>25,952</u> <u>31,917</u> <u>29,195</u> <u>32,814</u> <u>32,596</u> <u>30,113</u> <u>33,089</u> <u>33,096</u> <u>33,815</u> <u>34,040</u>
and:					
Address all correspondence to: <u>Ronald L. Grudziecki</u> <u>BURNS, DOANE, SWECKER & MATHIS, L.L.P.</u> <u>P.O. Box 1404</u> <u>Alexandria, Virginia 22313-1404</u>					
Address all telephone calls to: <u>Ronald L. Grudziecki</u> at (703) 836-6620.					
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.					

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (CONTINUED) (Includes Reference to Provisional and PCT International Applications)		ATTORNEY'S DOCKET NO.
FULL NAME OF SOLE OR FIRST INVENTOR <u>Dan HAUZENBERGER</u>		SIGNATURE <i>[Signature]</i>
RESIDENCE <u>Hägersten, Sweden SEX</u>		DATE <u>28/3 2001</u>
CITIZENSHIP <u>Swedish</u>		
POST OFFICE ADDRESS <u>Edsbergsgård 12, S-129 57 Hägersten, Sweden</u>		
FULL NAME OF SECOND JOINT INVENTOR, IF ANY		SIGNATURE
RESIDENCE		DATE
CITIZENSHIP		
POST OFFICE ADDRESS		
FULL NAME OF THIRD JOINT INVENTOR, IF ANY		SIGNATURE
RESIDENCE		DATE
CITIZENSHIP		
POST OFFICE ADDRESS		
FULL NAME OF FOURTH JOINT INVENTOR, IF ANY		SIGNATURE
RESIDENCE		DATE
CITIZENSHIP		
POST OFFICE ADDRESS		
FULL NAME OF FIFTH JOINT INVENTOR, IF ANY		SIGNATURE
RESIDENCE		DATE
CITIZENSHIP		
POST OFFICE ADDRESS		
FULL NAME OF SIXTH JOINT INVENTOR, IF ANY		SIGNATURE
RESIDENCE		DATE
CITIZENSHIP		
POST OFFICE ADDRESS		
FULL NAME OF SEVENTH JOINT INVENTOR, IF ANY		SIGNATURE
RESIDENCE		DATE
CITIZENSHIP		
POST OFFICE ADDRESS		
FULL NAME OF EIGHTH JOINT INVENTOR, IF ANY		SIGNATURE
RESIDENCE		DATE
CITIZENSHIP		
POST OFFICE ADDRESS		
FULL NAME OF NINTH JOINT INVENTOR, IF ANY		SIGNATURE
RESIDENCE		DATE
CITIZENSHIP		
POST OFFICE ADDRESS		